EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.801
https://www.valueinhealthjournal.com/article/S1098-3015(23)03931-1/fulltext
Title :
EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03931-1&doi=10.1016/j.jval.2023.09.801
First page :
Section Title :
Open access? :
No
Section Order :
10290